BioVision Lilly Award names winners
Four young scientists living and working in a developing country take the accolades
The winners were selected from among 40 entries by an international jury, chaired by Jacob Palis, president of TWAS, and professor at the Instituto Nacional de Matemática Pura e Aplicada in Rio de Janeiro, Brazil.
Digby Warner, senior research officer, MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, University of Cape Town, South Africa won the 2011 BioVision Lilly Award for his work on mycobacterial metabolism, which promises to have a major impact on understanding the development of drug-resistance in Mycobacterium tuberculosis.
The runner-up was Thomas Scriba, senior researcher, South African TB Vaccine Initiative, University of Cape Town, who was honoured for his work on TB vaccines.
The first- and second-place winners received US$5,000 and US$2,000, respectively, to continue their research.
Dihandenys Lemus, Tuberculosis National Reference Laboratory in Havana, Cuba and Joy Sarojini Michael, Christian Medical College of Vellore, India were joint third. Lemus was honoured for her work in drug-resistant tuberculosis and Michael for her research in new TB diagnostics.
‘We have been impressed with the quality of the competition and especially the winners,’ said Bart Peterson, senior vice-president, corporate affairs and communication, Eli Lilly and Company.
‘TB largely afflicts the developing world and I’m heartened to see that young developing world scientists are taking their position at the forefront of global research being carried out into this debilitating disease.’
In 2009 more than nine million people became ill with TB and some 1.7 million died of the disease. The number of new cases arising each year is still increasing in Africa, Eastern Mediterranean and South-East Asia.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Research & Development
VoxCell BioInnovation and adMare partner to validate bioprinted vascularised cancer tissue models for antibody therapy development
The pair have announced a research collaboration using VoxCell's human-relevant bioprinted vascularised cancer tissue models to validate a novel antibody-based immune-modulating therapy, as the FDA advances plans to reduce animal testing for monoclonal antibodies through New Approach Methodologies
Research & Development
Brainomix and Boehringer Ingelheim continue partnership in pulmonary fibrosis
The pair will advance their strategic partnership to the next phase of clinical trials for Brainomix's e-Lung after strong initial results demonstrated its potential to enable earlier diagnosis of progressive pulmonary fibrosis